{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:08:08Z","timestamp":1772482088818,"version":"3.50.1"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:p>The proven effectiveness of biologics and other immunomodulatory products in inflammatory rheumatic diseases has resulted in their widespread use as well as reports of potential short- and long-term complications such as infection and malignancy. These complications are especially worrisome in children who often have serial exposures to multiple immunomodulatory products. Post-marketing surveillance of immunomodulatory products in juvenile idiopathic arthritis (JIA) and pediatric systemic lupus erythematosus is currently based on product-specific registries and passive surveillance, which may not accurately reflect the safety risks for children owing to low numbers, poor long-term retention, and inadequate comparators. In collaboration with the US Food and Drug Administration (FDA), patient and family advocacy groups, biopharmaceutical industry representatives and other stakeholders, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and the Duke Clinical Research Institute (DCRI) have developed a novel pharmacosurveillance model (CARRA Consolidated Safety Registry [CoRe]) based on a multicenter longitudinal pediatric rheumatic diseases registry with over 8000 participants. The existing CARRA infrastructure provides access to much larger numbers of subjects than is feasible in single-product registries. Enrollment regardless of medication exposure allows more accurate detection and evaluation of safety signals. Flexibility built into the model allows the addition of specific data elements and safety outcomes, and designation of appropriate disease comparator groups relevant to each product, fulfilling post-marketing requirements and commitments. The proposed model can be applied to other pediatric and adult diseases, potentially transforming the paradigm of pharmacosurveillance in response to the growing public mandate for rigorous post-marketing safety monitoring.<\/jats:p>","DOI":"10.1542\/peds.2013-0755","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:48:33Z","timestamp":1382402913000},"page":"e1384-e1394","source":"Crossref","is-referenced-by-count":24,"title":["Using Registries to Identify Adverse Events in Rheumatic Diseases"],"prefix":"10.1542","volume":"132","author":[{"given":"Geraldina","family":"Lionetti","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Stanford University, Palo Alto, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Schanberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University Medical Center, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seattle Children\u2019s Hospital, Seattle, Washington;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman T.","family":"Ilowite","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital at Montefiore, Bronx, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Winsor","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Fox","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Natter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Boston Children\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Sundy","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Silver Spring, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Del Gaizo","sequence":"additional","affiliation":[{"name":"Friends of Childhood Arthritis and Rheumatology Research Alliance, Whitehouse Station, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Iyasu","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Silver Spring, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Jahreis","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Meeker-O\u2019Connell","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Silver Spring, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara B.","family":"Mittleman","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Arthritis Foundation, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra C.","family":"Raymond","sequence":"additional","affiliation":[{"name":"Lupus Foundation of America, Washington, District of Columbia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soko","family":"Setoguchi","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey N.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Friends of Childhood Arthritis and Rheumatology Research Alliance, Whitehouse Station, New Jersey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Sobel","sequence":"additional","affiliation":[{"name":"Pfizer, Inc, New York, New York;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Brigham & Women\u2019s Hospital, Boston, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taunton R.","family":"Southwood","sequence":"additional","affiliation":[{"name":"School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Vesely","sequence":"additional","affiliation":[{"name":"European Medicines Agency, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patience H.","family":"White","sequence":"additional","affiliation":[{"name":"Arthritis Foundation, Atlanta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico M.","family":"Wulffraat","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy I.","family":"Sandborg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University, Palo Alto, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"issue":"1","key":"2021120903034361800_B1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar2619","article-title":"Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis.","volume":"11","author":"Hayward","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2021120903034361800_B2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120903034361800_B3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"2021120903034361800_B4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1542\/peds.2007-1529","article-title":"Improving pediatric dosing through pediatric initiatives: what we have learned.","volume":"121","author":"Rodriguez","year":"2008","journal-title":"Pediatrics"},{"issue":"8","key":"2021120903034361800_B5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2021120903034361800_B6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021120903034361800_B7"},{"issue":"9","key":"2021120903034361800_B8","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/acr.21709","article-title":"Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents.","volume":"64","author":"Nordstrom","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"2021120903034361800_B9","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.27741","article-title":"Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.","volume":"62","author":"Simard","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2021120903034361800_B10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.100711","article-title":"Malignancies in juvenile idiopathic arthritis: a preliminary report.","volume":"38","author":"Bernatsky","year":"2011","journal-title":"J Rheumatol"},{"issue":"6","key":"2021120903034361800_B11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J Pediatr"},{"issue":"7","key":"2021120903034361800_B12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3899\/jrheum.100809","article-title":"Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.","volume":"38","author":"van Dijken","year":"2011","journal-title":"J Rheumatol"},{"key":"2021120903034361800_B13","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis; from the Safety Assessment of Biologic ThERapy (SABER) Study.","author":"Winthrop","year":"2012;","journal-title":"Am J Ophthalmol"},{"key":"2021120903034361800_B14"},{"key":"2021120903034361800_B15","article-title":"Pediatric studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act","volume-title":"Institute of Medicine","author":"Safe and Effective Medicines for Children","year":"2012"},{"key":"2021120903034361800_B16"},{"issue":"2","key":"2021120903034361800_B17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.clpt.6100285","article-title":"Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.","volume":"82","author":"Mathis","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2021120903034361800_B18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-0585","article-title":"Safety monitoring of drugs receiving pediatric marketing exclusivity.","volume":"122","author":"Smith","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"2021120903034361800_B19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1542\/peds.2012-2412","article-title":"IOM Review of FDA\u2014approved biologics labeled or studied for pediatric use.","volume":"131","author":"Field","year":"2013","journal-title":"Pediatrics"},{"key":"2021120903034361800_B20"},{"issue":"8","key":"2021120903034361800_B21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"2021120903034361800_B22","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"2021120903034361800_B23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"2021120903034361800_B24","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2021120903034361800_B25","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021120903034361800_B26"},{"key":"2021120903034361800_B27"},{"issue":"6","key":"2021120903034361800_B28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.20128","article-title":"Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry.","volume":"62","author":"Smith","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2021120903034361800_B29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/amiajnl-2012-001042","article-title":"An i2b2-based, generalizable, open source, self-scaling chronic disease registry.","volume":"20","author":"Natter","year":"2013","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"2021120903034361800_B30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1197\/jamia.M3191","article-title":"The Shared Health Research Information Network (SHRINE): a prototype federated query tool for clinical data repositories.","volume":"16","author":"Weber","year":"2009","journal-title":"J Am Med Inform Assoc"},{"key":"2021120903034361800_B31","doi-asserted-by":"crossref","DOI":"10.4103\/2153-3539.68314","article-title":"A decade of experience in the development and implementation of tissue banking informatics tools for intra and inter-institutional translational research.","volume":"1","author":"Amin","year":"2010","journal-title":"J Pathol Inform"},{"issue":"12","key":"2021120903034361800_B32","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3899\/jrheum.120642","article-title":"Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry.","volume":"39","author":"Weiss","year":"2012","journal-title":"J Rheumatol"},{"issue":"9","key":"2021120903034361800_B33","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3899\/jrheum.120110","article-title":"Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.","volume":"39","author":"Beukelman","year":"2012","journal-title":"J Rheumatol"},{"issue":"6","key":"2021120903034361800_B34","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3899\/jrheum.121147","article-title":"Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.","volume":"40","author":"Ringold","year":"2013","journal-title":"J Rheumatol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/5\/e1384\/1100058\/peds_2013-0755.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/132\/5\/e1384\/1100058\/peds_2013-0755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T16:42:44Z","timestamp":1639068164000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/132\/5\/e1384\/31729\/Using-Registries-to-Identify-Adverse-Events-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,11,1]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2013-0755","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}